Disclosures: Harsh Tevethia: Nothing to Disclose, Akhil Deshmukh: Nothing to Disclose, Ankur Jindal: Nothing to Disclose, Guresh Kumar: Nothing to Disclose, Shiv Kumar Sarin: Nothing to Disclose 2264 PATIENTS WITH CIRRHOSIS AND A HISTORY OF OVERT HEPATIC ENCEPHALOPATHY EXPERIENCED LOWER 6-MONTH ALL-CAUSE MORTALITY RATES WITH RIFAXIMIN MONOTHERAPY VERSUS LACTULOSE MONOTHERAPY Jasmohan Bajaj 1 Robert Rahimi 2 Christopher Allen 3 Zeev Heimanson 3 Robert Israel 3 Kris Kowdley 4 , 1 Virginia Commonwealth University and Central Virginia Veterans Healthcare System, 2 Baylor University Medical Center, 3 Salix Pharmaceuticals, 4 Liver Institute Northwest and Elson Floyd College of Medicine Background: Hepatic encephalopathy (HE) is associated with a poor prognosis, and data suggest that rifaximin use may improve survival
and BAGSVRD, Denmark, June 7, 2026 /PRNewswire/ -- Phase 3 results from Novo Nordisk's REIMAGINE 1-3 trials were presented today, showing significant reduction in HbA 1c and weight in adults with type 2 diabetes (T2D)
Most clinical protocols recommend 500 to 1000 IU administered one to three times weekly
Harding CF, Pytte CL, Page KG, Ryberg KJ, Normand E, Remigio GJ, DeStefano RA, Morris DB, Voronina J, Lopez A, Stalbow LA, Williams EP, Abreu N
The realistic picture: B12 shots do not directly burn fat, but they correct a deficiency that can quietly work against you
Takahashi, S
